Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From ItSeeking Alpha · Oct 11, 2026
Latigo Biotherapeutics (NASDAQ:LTGO) Hits New 12-Month Low – Here’s WhyDefense World · Oct 8, 2026
Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)Defense World · Sep 9, 2026
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire · Sep 3, 2026
Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public24/7 Wall Street · Aug 13, 2026
Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 SharesDefense World · Aug 11, 2026Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.